Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perrigo launches generic Zaditor

This article was originally published in The Tan Sheet

Executive Summary

Perrigo ships its generic of Novartis Pharmaceuticals' Zaditor, a ketotifen fumarate ophthalmic solution, .025 percent, the Allegan, Mich.-based private labeler says in a March 15 release. Perrigo CEO Joseph Papa said the firm is "excited to launch into a new adjacent OTC category, ophthalmics." Zaditor is a solution used to temporarily prevent allergic conjunctivitis. Wolters Kluwer data estimates the annual sales of Zaditor in the last 12 months reached $15 million, Perrigo said. Competition in the eye-care market increased with the recent launch of Johnson & Johnson/McNeil's Zyrtec Allergy Eye Relief Drops and Schering-Plough's Claritin Eye, which also contain ketotifen fumarate as the active ingredient (1"The Tan Sheet" Jan. 11, 2010)
Advertisement

Related Content

Zyrtec and Claritin Eye Drops Use Different Tactics In Head To Head Fight
Zyrtec and Claritin Eye Drops Use Different Tactics In Head To Head Fight

Topics

Advertisement
UsernamePublicRestriction

Register

PS103923

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel